Evidence map›Paper›PMID 32198587›Full record

ReviewPediatric cardiology2020

The Potential Impact and Timeline of Engineering on Congenital Interventions.

Matthew R Russell, Benjamin Blais, Nima Nia, Daniel S Levi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pediatric cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Matthew R RussellDivision of Cardiology, Department of Pediatrics, UCLA Mattel Children's Hospital, Los Angeles, CA, USA.
Benjamin BlaisDivision of Cardiology, Department of Pediatrics, UCLA Mattel Children's Hospital, Los Angeles, CA, USA.
Nima NiaDepartment of Bioengineering, UCLA Samueli School of Engineering, UCLA, Los Angeles, CA, USA.
Daniel S LeviDivision of Cardiology, Department of Pediatrics, UCLA Mattel Children's Hospital, Los Angeles, CA, USA. dlevi@mednet.ucla.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congenital interventional cardiology has seen rapid growth in recent decades due to the expansion of available medical devices. Percutaneous interventions have become standard of care for many common congenital conditions. Unfortunately, patients with congenital heart disease often require multiple interventions throughout their lifespan. The availability of transcatheter devices that are biodegradable, biocompatible, durable, scalable, and can be delivered in the smallest sized patients will rely on continued advances in engineering. The development pipeline for these devices will require contributions of many individuals in academia and industry including experts in material science and tissue engineering. Advances in tissue engineering, bioresorbable technology, and even new nanotechnologies and nitinol fabrication techniques which may have an impact on the field of transcatheter congenital device in the next decade are summarized in this review. This review highlights recent advances in the engineering of transcatheter-based therapies and discusses future opportunities for engineering of transcatheter devices.

Indexed as

Cardiac CatheterizationHeart Defects, CongenitalHumansTissue EngineeringCatheter interventionsCongenital heart diseaseEngineeringTissue engineering

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.